Diagnostic performance of microRNAs for predicting response to transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis

Tianyi Huang, Jing Chen, Pengfei Zhang, Rui Wang, Yiheng Liu, Cuihua LuFrontiers in Oncology 2025 · DOI

Abstract

MicroRNAs (miRNAs) show significant promise as non-invasive diagnostic tools for predicting treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). This meta-analysis evaluates their current diagnostic performance and identifies critical steps for clinical implementation. While initial results are encouraging, future research must prioritize the standardization of RNA extraction methods, the selection of consistent endogenous controls, and the adoption of uniform response evaluation criteria to improve reliability and reduce inter-study variability.

Introduction

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. For patients diagnosed with intermediate-stage tumors, Transarterial Chemoembolization (TACE) is the standard of care. TACE works by delivering chemotherapy directly to the tumor while simultaneously obstructing its blood supply. However, patient response to TACE is highly variable, and current methods for evaluating success—primarily CT or MRI imaging—can be expensive, difficult to interpret consistently, and are often only useful well after the procedure has been completed.

There is a pressing clinical need for molecular biomarkers that can predict treatment response early. Circulating microRNAs (miRNAs) have emerged as a potential "liquid biopsy" solution, offering a non-invasive way to personalize therapy and improve patient outcomes by identifying those most likely to benefit from TACE versus those who should pivot to alternative treatments like sorafenib.

Methods and Study Selection

The researchers conducted a comprehensive systematic meta-analysis following the PRISMA-DTA guidelines. They aggregated data from major scientific databases, including PubMed, Embase, Cochrane Library, and Web of Science, for studies published through July 2024.

PRISMA flowchart of the study selection process.

As illustrated in the study selection flowchart, the initial search identified 392 records. After removing duplicates and screening for specific inclusion criteria—such as the presence of ROC/AUC analysis and sufficient raw data—seven independent studies were selected for the final analysis. These studies encompassed 507 patients (320 responders and 187 non-responders) across diverse geographic regions, including China, Egypt, and Italy. The specific biomarkers evaluated included miR-373, miR-210, miR-4492, miR-1271, miR-214, miR-133b, and miR-335.

Key Biological Insights

A major finding of this meta-analysis is that while individual studies focused on different specific miRNAs, the collective diagnostic signal remained remarkably consistent. This suggests that miRNA dysregulation is a robust general feature of TACE resistance and response.

The study highlighted the distinct roles of these molecules:

  • Oncogenic miRNAs: Molecules such as miR-210 and miR-373 promote tumor growth; their levels typically drop significantly following successful TACE.
  • Tumor-suppressive miRNAs: Molecules like miR-1271 and miR-214 are often downregulated in HCC patients, but their restoration may indicate a better prognosis.

Additionally, the choice of evaluation criteria was found to be a significant variable. Studies using RECIST criteria showed higher diagnostic accuracy than those using mRECIST, likely due to differences in how these frameworks define tumor necrosis and overall response.

Quantitative Results and Clinical Impact

The meta-analysis provided strong quantitative evidence for the efficacy of miRNAs as biomarkers:

  • Pooled Sensitivity: 0.79 [95% CI: 0.72–0.84]
  • Pooled Specificity: 0.82 [95% CI: 0.74–0.88]
  • Overall Accuracy: The pooled area under the curve (AUC) was 0.85, which is considered "excellent" for diagnostic applications.
  • Diagnostic Odds Ratio (DOR): 17, indicating that a positive miRNA test result is associated with a 17-fold increase in the odds of correctly identifying a treatment responder.

To illustrate the clinical utility, the researchers used a Fagan’s nomogram. For a patient with a 25% baseline probability of responding to TACE, a positive miRNA test result would increase that probability to 60%, providing clinicians with actionable data for treatment planning.

Limitations and Future Directions

Despite the promising data, several hurdles remain before miRNA testing can be integrated into routine clinical practice. The current evidence base is limited by a small total sample size and a geographical bias toward cohorts in China and Egypt. Furthermore, there is a significant lack of standardization regarding RNA extraction techniques and the "housekeeping" genes used for normalization.

Moving forward, large-scale, multicenter prospective trials are required to validate these findings across more diverse populations and to establish standardized laboratory protocols. Only through such rigorous validation can these molecular markers transition from the laboratory to the clinic as a reliable tool for personalized cancer therapy.

Summary updated

Abstract

MiRNAs show promise as diagnostic tools for predicting TACE response in HCC patients. However, their clinical application requires further validation in larger cohorts. Future research should focus on standardizing RNA extraction methods, selecting consistent endogenous controls, and adopting uniform response evaluation criteria to improve reliability and reduce variability.
BibTeX
@inproceedings{huang2025diagnostic,
  author = {Tianyi Huang and Jing Chen and Pengfei Zhang and Rui Wang and Yiheng Liu and Cuihua Lu},
  title = {{Diagnostic performance of microRNAs for predicting response to transarterial chemoembolization in hepatocellular carcinoma: a meta-analysis}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2024.1483196},
}
Figure